Thrivent Financial for Lutherans’s Tvardi Therapeutics TVRD Stock Holding History

Thrivent Financial for Lutherans’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,243	Closed	-$220K	–	2552
2023 Q1	$220K	Sell	1,243 -43	-3%	-$14.4K	﹤0.01%	2364
2022 Q4	$497K	Sell	1,286 -10	-0.8%	-$3.8K	﹤0.01%	2122
2022 Q3	$437K	Buy	1,296 +141	+12%	+$51.1K	﹤0.01%	2119
2022 Q2	$380K	Buy	1,155 +208	+22%	+$73K	﹤0.01%	2194
2022 Q1	$414K	Sell	947 -8	-0.8%	-$3.28K	﹤0.01%	2259
2021 Q4	$419K	Buy	955 +10	+1%	+$5.03K	﹤0.01%	2241
2021 Q3	$525K	Sell	945 -32	-3%	-$16.1K	﹤0.01%	2160
2021 Q2	$502K	Buy	+977	New	+$619K	﹤0.01%	2179

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thrivent Financial for Lutherans's TVRD Position: Q2 2023 in Review

Thrivent Financial for Lutherans sold out of Tvardi Therapeutics (TVRD) in Q2 2023, closing a stake of 1,243 shares — an estimated $220K sold.

Thrivent Financial for Lutherans first reported a position in TVRD in Q2 2021 and held it in 8 quarters. The position peaked at $525K in Q3 2021. 137 funds tracked by Wall St. Rank hold TVRD as of Q2 2023.

Thrivent Financial for Lutherans reported no remaining Tvardi Therapeutics position as of Q2 2023 after selling out during the quarter.
Thrivent Financial for Lutherans sold 1,243 Tvardi Therapeutics shares in Q2 2023, an estimated $220K.
Thrivent Financial for Lutherans first reported a position in Tvardi Therapeutics in Q2 2021 and held it in 8 quarters.
Thrivent Financial for Lutherans's Tvardi Therapeutics position peaked at $525K in Q3 2021.
137 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2023, filed 14 Aug 2023.